ZAI LAB LIMITED Foreign Currency Transaction Gain (Loss), before Tax
ZAI LAB LIMITED (ZLAB) reported Foreign Currency Transaction Gain (Loss), before Tax of $15.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-06
- ZAI LAB LIMITED foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $15.06M, a 431.02% increase year-over-year.
- ZAI LAB LIMITED foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was $14.84M, a 2179.11% increase year-over-year.
- ZAI LAB LIMITED foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $9.68M.
- ZAI LAB LIMITED foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $6.42M, a 55.58% decline year-over-year.
- ZAI LAB LIMITED foreign currency transaction gain (loss), before tax for fiscal 2025 was $19.59M.
- ZAI LAB LIMITED foreign currency transaction gain (loss), before tax for fiscal 2024 was -$15.14M.
- ZAI LAB LIMITED foreign currency transaction gain (loss), before tax for fiscal 2023 was -$14.85M.
- ZAI LAB LIMITED foreign currency transaction gain (loss), before tax for fiscal 2022 was -$56.40M, a 1310.11% decline from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.06M 10-Q · filed 2026-08-06 | $29.90M 10-Q · filed 2026-08-06 | $39.58M derived: sum of 3 quarters · filed 2026-08-06 | $46.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.84M 10-Q · filed 2026-05-07 | $24.52M derived: sum of 2 quarters · filed 2026-05-07 | $30.94M derived: sum of 3 quarters · filed 2026-05-07 | $33.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $9.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.10M derived: sum of 2 quarters · filed 2026-02-26 | $18.94M derived: sum of 3 quarters · filed 2026-08-06 | $19.59M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.42M 10-Q · filed 2025-11-06 | $9.26M derived: sum of 2 quarters · filed 2026-08-06 | $9.91M 10-Q · filed 2025-11-06 | -$13.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.84M 10-Q · filed 2026-08-06 | $3.49M 10-Q · filed 2026-08-06 | -$19.93M derived: sum of 3 quarters · filed 2026-08-06 | -$5.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $651.00K 10-Q · filed 2026-05-07 | -$22.77M derived: sum of 2 quarters · filed 2026-05-07 | -$8.31M derived: sum of 3 quarters · filed 2026-05-07 | -$12.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$23.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$8.96M derived: sum of 2 quarters · filed 2026-02-26 | -$13.07M derived: sum of 3 quarters · filed 2026-02-26 | -$15.14M 10-K · filed 2026-02-26 |
| 2024-09-30 | $14.46M 10-Q · filed 2025-11-06 | $10.35M derived: sum of 2 quarters · filed 2025-11-06 | $8.28M 10-Q · filed 2025-11-06 | $19.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$4.11M 10-Q · filed 2025-08-07 | -$6.18M 10-Q · filed 2025-08-07 | $5.29M derived: sum of 3 quarters · filed 2026-02-26 | $10.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$2.07M 10-Q · filed 2025-05-08 | $9.40M derived: sum of 2 quarters · filed 2026-02-26 | $14.25M derived: sum of 3 quarters · filed 2026-02-26 | -$25.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $11.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.32M derived: sum of 2 quarters · filed 2026-02-26 | -$23.76M derived: sum of 3 quarters · filed 2026-02-26 | -$14.85M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.85M 10-Q · filed 2024-11-12 | -$35.23M derived: sum of 2 quarters · filed 2024-11-12 | -$26.32M 10-Q · filed 2024-11-12 | -$9.67M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$40.08M 10-Q · filed 2024-08-06 | -$31.17M 10-Q · filed 2024-08-06 | -$14.52M derived: sum of 3 quarters · filed 2025-02-27 | -$54.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $8.91M 10-Q · filed 2024-05-08 | $25.56M derived: sum of 2 quarters · filed 2025-02-27 | -$14.88M derived: sum of 3 quarters · filed 2025-02-27 | -$49.78M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $16.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$23.79M derived: sum of 2 quarters · filed 2025-02-27 | -$58.69M derived: sum of 3 quarters · filed 2025-02-27 | -$56.40M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$40.44M 10-Q · filed 2023-11-07 | -$75.34M derived: sum of 2 quarters · filed 2023-11-07 | -$73.05M 10-Q · filed 2023-11-07 | -$65.55M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$34.90M 10-Q · filed 2023-08-07 | -$32.61M 10-Q · filed 2023-08-07 | -$25.11M derived: sum of 3 quarters · filed 2024-02-27 | |
| 2022-03-31 | $2.29M 10-Q · filed 2023-05-09 | $9.78M derived: sum of 2 quarters · filed 2024-02-27 | ||
| 2021-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.66M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | -$2.84M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $21.66M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |